Terapet receives €500K Eurostars award allocated to clinical validation

Terapet together with their clinical partners, ranked 2 out of 500 projects across Europe by European Commission, receives a total €700K (500K to Terapet) non-dilutive grant to continue on their successful path. The grant will finance a 3-year consortium between Terapet and the Nobel Prize-awarding Karolinska Institute, one of the world’s most prestigious medical universities, and the Skandion Clinic – Scandinavia’s first proton therapy facility.

Terapet is developing and commercializing innovative solutions for a safer, more precise and time-saving proton therapy for cancer treatment. Terapet's novel medical device will enable medical doctors to monitor the delivered proton dose inside the patients during cancer treatment, ensuring that every patient receives the right dose, every time.

Christina Vallgren, CEO and Co-founder of Terapet explains "We are very thankful and honored for this award. It will help us take the next steps and specifically, this consortium will focus on the clinical validation for our prototype towards CE-certification."

Terapet has been supported by both Venture Kick and Venture Leaders. Christina Vallgren, says “Venturekick has provided us with the business tools and knowledge we never had the opportunity to learn as physicists. The Venturekick program accelerated our idea and made it possible to transform it into a real venture! Additionally, Venturekick has been playing an important role in our company progress where we met several of our investors from the pitch sessions"